Literature DB >> 33129690

Toll-like receptor mediated lysozyme expression in Niemann-pick disease, type C1.

Antony Cougnoux1, Julia C Yerger1, Mason Fellmeth1, Jenny Serra-Vinardell2, Christopher A Wassif1, Niamh X Cawley1, Forbes D Porter3.   

Abstract

Niemann-Pick type C1 (NPC1) is a rare neurodegenerative disease. In NPC1 mouse cerebella, the antibacterial enzyme, lysozyme (Lyz2), is significantly increased in multiple cell types. Due to its possible role in toxic fibril deposition, we confirmed Lyz2 overexpression in culture in different control and NPC1 cell types including human NPC1 fibroblasts. Lyz2 expression is induced by Toll-like receptors potentially in response to lipid storage but does not play a functional role in NPC disease pathology. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33129690      PMCID: PMC7736542          DOI: 10.1016/j.ymgme.2020.10.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  21 in total

1.  Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain.

Authors:  Roland Distl; Stephanie Treiber-Held; Frank Albert; Volker Meske; Klaus Harzer; Thomas G Ohm
Journal:  J Pathol       Date:  2003-05       Impact factor: 7.996

2.  Isolation and culture of mouse cortical astrocytes.

Authors:  Sebastian Schildge; Christian Bohrer; Kristina Beck; Christian Schachtrup
Journal:  J Vis Exp       Date:  2013-01-19       Impact factor: 1.355

3.  Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene.

Authors:  S K Loftus; J A Morris; E D Carstea; J Z Gu; C Cummings; A Brown; J Ellison; K Ohno; M A Rosenfeld; D A Tagle; P G Pentchev; W J Pavan
Journal:  Science       Date:  1997-07-11       Impact factor: 47.728

Review 4.  Niemann-Pick disease type C.

Authors:  Marie T Vanier
Journal:  Orphanet J Rare Dis       Date:  2010-06-03       Impact factor: 4.123

5.  Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention.

Authors:  Antony Cougnoux; Rebecca A Drummond; Amanda L Collar; James R Iben; Alexander Salman; Harrison Westgarth; Christopher A Wassif; Niamh X Cawley; Nicole Y Farhat; Keiko Ozato; Michail S Lionakis; Forbes D Porter
Journal:  Hum Mol Genet       Date:  2018-06-15       Impact factor: 6.150

6.  Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy.

Authors:  Kazuhiro Ohmi; Lili C Kudo; Sergey Ryazantsev; Hui-Zhi Zhao; Stanislav L Karsten; Elizabeth F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-05       Impact factor: 11.205

7.  Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice.

Authors:  Ian M Williams; Kerri-Lee Wallom; David A Smith; Nada Al Eisa; Claire Smith; Frances M Platt
Journal:  Neurobiol Dis       Date:  2014-03-12       Impact factor: 5.996

8.  Complement is dispensable for neurodegeneration in Niemann-Pick disease type C.

Authors:  Manuel E Lopez; Andres D Klein; Matthew P Scott
Journal:  J Neuroinflammation       Date:  2012-09-17       Impact factor: 8.322

9.  Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection.

Authors:  Feiran Lu; Qiren Liang; Lina Abi-Mosleh; Akash Das; Jef K De Brabander; Joseph L Goldstein; Michael S Brown
Journal:  Elife       Date:  2015-12-08       Impact factor: 8.140

10.  Identification of Novel Pathways Associated with Patterned Cerebellar Purkinje Neuron Degeneration in Niemann-Pick Disease, Type C1.

Authors:  Kyle B Martin; Ian M Williams; Celine V Cluzeau; Antony Cougnoux; Ryan K Dale; James R Iben; Niamh X Cawley; Christopher A Wassif; Forbes D Porter
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

View more
  1 in total

1.  Single-cell mapping of focused ultrasound-transfected brain.

Authors:  A S Mathew; C M Gorick; R J Price
Journal:  Gene Ther       Date:  2021-02-01       Impact factor: 4.184

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.